Aphaia Pharma

Aphaia Pharma is a clinical-stage biopharmaceutical company leveraging proprietary precision-targeted delivery technology to restore endogenous hormone release in the gastrointestinal tract for the treatment and prevention of metabolic disorders such as obesity and related conditions. Aphaia’s lead candidate drug, APH-012, is a glucose formulation that has been shown to safely restore endogenous hormone release in obese individuals. Currently, APH-012 is undergoing Phase 2 clinical trials for chronic weight management in the United States and Germany, and preparations are underway for a second Phase 2 clinical trial aimed at improving pathological oral glucose tolerance test (OGTT) responses in prediabetic patients. The versatile design of Aphaia’s technology platform offers opportunities for developing treatments across multiple disease models.